Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
Date
2025
Authors
Sandhu, G.
Adattini, J.
Armstrong Gordon, E.
O'Neill, N.
Boddy, A.V.
Ward, R.L.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
EClinicalMedicine, 2025; 82(103161):1-11
Statement of Responsibility
Conference Name
Abstract
Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders,‘change championing’ by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems.
School/Discipline
Dissertation Note
Provenance
Description
Data source: supplementary data, https://ars.els-cdn.com/content/image/1-s2.0-S2589537025000938-mmc1.docx
Access Status
Rights
Copyright 2025 the Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)